

## CURRICULUM VITAE

**RITA R. ALLOWAY, Pharm.D., BCPS**

### OFFICE ADDRESS

College of Medicine  
 Department of Internal Medicine  
 Div. of Nephrology & Hypertension  
 231 Albert Sabin Way  
 Medical Sciences Building  
 Suite 3410, ML 585  
 P.O. Box 670585  
 Cincinnati Ohio 45267-0585  
 Office: 513.558.1568  
 Fax: 513.558.4309  
 Email: rita.alloway@uc.edu

### EDUCATION AND TRAINING

Vanderbilt University Medical Center	Immunotherapeutics Traineeship September 1993
Veteran's Administration Medical Center Memphis, Tennessee	ASHP Approved General Clinical Residency August 1988-July 1989
University of Tennessee College of Pharmacy Memphis, Tennessee	Doctor of Pharmacy 1984-1988
Oral Roberts University Tulsa, Oklahoma	Pre-Pharmacy Curriculum 1982-1984
Riverside High School Parsons, Tennessee	1979-1982

### PHARMACIST LICENSURE

Tennessee State Board of Pharmacy	1988 C007391
Ohio State Board of Pharmacy	2001 03-1-24472

**PROFESSIONAL CERTIFICATION**

Board Certified Pharmacotherapy Specialist      1994    294229

**ACADEMIC APPOINTMENTS**

July 2000-present      Research Professor  
 College of Medicine  
 Department of Internal Medicine  
 Div. of Nephrology and Hypertension  
 Section of Transplantation  
 University of Cincinnati

July 1997-July 2000      Associate Professor  
 College of Pharmacy  
 Department of Clinical Pharmacy  
 University of Tennessee, Memphis

July 1997-July 2000      Associate Professor  
 College of Medicine  
 Department of Surgery  
 University of Tennessee, Memphis

August 1989-June 1997      Assistant Professor  
 College of Pharmacy  
 Department of Clinical Pharmacy  
 University of Tennessee, Memphis

**ADMINISTRATIVE APPOINTMENTS: HOSPITAL**

April 1999-July 1999      Diabetes Advisory Committee  
 UT Bowld Hospital

July 1997-July 2000      Clinical Pharmacy Group  
 UT Bowld Hospital

April 1996-July 1999      JCAHO Steering Team  
 UT Bowld Hospital

April 1996-July 1999      Closed Medical Record Review

	UT Bowld Hospital
April 1996-July 1997 July 1999-July 2000	Infection Control Committee UT Bowld Hospital
September 1995- July 2000	Acting Director, Clinical Pharmacy Services UT Bowld Hospital
January 1992-1993	Secretary, Inpatient Clinical Practice Committee UT Bowld Hospital
January 1992-1993	Clinical Research Working Group UT Bowld Hospital
July 1991-1994	Educational Advisory Committee UT Bowld Hospital
July 1990-July 1999	Secretary, Pharmacy & Therapeutics Committee UT Bowld Hospital

#### **ADMINISTRATIVE APPOINTMENTS: ACADEMIC**

December 2000-present	Clinical Trials Committee University of Cincinnati College of Medicine
August 2000-Present	Director, Transplant Clinical Research College of Medicine University of Cincinnati
May 1999- July 2000	Clinical Trials Committee TriStar Enterprises, Inc.
January 1999- July 2000	Residency Committee College of Pharmacy University of Tennessee

January 1999-2000	Departmental Chair Recruitment Committee College of Pharmacy University of Tennessee
January 1999-April 1999	Faculty Recruitment Committee College of Pharmacy University of Tennessee
June 1997- July 2000	Director, Transplant Research Institute College of Medicine University of Tennessee
January 1994	Drug Information Course Committee College of Pharmacy University of Tennessee

### **CLINICAL PRACTICE**

August 1989- July 2000	Clinical Pharmacist UT Bowld Hospital
January 1989- December 1991 December 1988-October 1991	Nursing Home Consultant Pharmacist Poison Information Specialist Southern Poison Center

### **EDITORIAL REVIEW**

Critical Care Nursing	1992-present
Abstract reviewer, ACCP Annual Meeting,	1996-present
PSAP Chapter reviewer, ACCP	1997.
PSAP Chapter author, ACCP	1998.

### **SCHOLASTIC HONORS**

Pharmacy School Honor Council Vice President  
Outstanding Young Women of American  
Transplant Pharmacist Profile

### **PROFESSIONAL SOCIETIES**

American Society of Transplant Physicians  
American College of Clinical Pharmacy

Immunology/Transplant PRN Chair	1998
Mid-South College of Clinical Pharmacy President	1996
President Elect	1995
American Society of Hospital Pharmacists	
American Pharmaceutical Association	
Rho Chi Pharmaceutical Honor Society	
Beta Beta Beta Biological Honor Society	

## **CORPORATE ADVISORY COMMITTEES**

SangStat Medical Corporation Pharmacy Advisory Board, Chairman.  
 Biogen Pharmaceutical Corporation, Anti-CD40 Ligand Scientific Advisory Board  
 Protein Design Labs  
 Abbott Pharmaceutical Corporation  
 Tristar Enterprises, Inc. Clinical Trials Committee  
 Fujisawa Clinical Pharmacy Advisory Group  
 Roche Clinical Pharmacy Advisory Group

## **FELLOWS TRAINED**

Agnes Lo, Pharm.D. Transplantation Fellowship	August 1999-2000
--	------------------

## **RESIDENTS TRAINED: PRIMARY PRECEPTOR**

Meridith Aull, PharmD Transplantation Specialty Residency	August 2000-2001
Karen Hardinger, Pharm.D. Transplantation Specialty Residency	August 1999-2000
Marsha Honaker, Pharm.D. Transplantation Specialty Residency	August 1999-2000
Agnes Lo, Pharm.D. Transplantation Specialty Residency	August 1998-1999
Jennifer Trofe, Pharm.D. Transplantation Specialty Residency	June 1998-1999
Troy Somerville, Pharm.D. Transplantation Specialty Residency	July 1997-1998
Chris Hurst, Pharm.D.	March 1997-1998

Transplantation Specialty Residency

Mark Chaballa, Pharm.D.  
Transplantation Specialty Residency

July 1996-1997

James Thielke, Pharm.D.  
Transplantation Specialty Residency

July 1995 - July 1996

Wendy Russell, Pharm.D.  
Transplantation Specialty Residency

July 1994 - July 1995

### **RESIDENTS TRAINED: CO-PRECEPTOR**

(Co-precepted with primary preceptor Timothy Self, Pharm.D.)

Kutay Demirkan, Pharm.D.  
Internal Medicine Therapeutics

July 1998-1999

Steve Nolan, Pharm.D.  
Internal Medicine Therapeutics

July 1997-1998

Valerie Strayhorn, Pharm.D.  
Internal Medicine Therapeutics

July 1996-1997

Cheryl Corley, Pharm.D.  
Internal Medicine Therapeutics

July 1994 - July 1995

Richard Jennings, Pharm.D.  
Internal Medicine Therapeutics

July 1993 - July 1994

Greta Heiliker, Pharm.D.  
Internal Medicine Therapeutics

July 1992 - July 1993

Tiffany Kelso, Pharm.D.  
Internal Medicine Therapeutics

July 1991 - July 1992

Ronald Joe, Pharm.D.

July 1990 – July 1991

**PUBLICATIONS**

1. Kelso TM, **Alloway RR**, Self TH. Asthma Patient Education, *Journal of Pharmacy Practice* 5: 186-196, 1992.
2. **Alloway RR**, Kotb M, Gaber L, Boskey F, Gaber AO. Standard Versus Low Dose OKT3 Induction of Cadaveric Renal Transplants: Comparison of Outcome Data versus OKT3 Dose and Serum Levels. *Clin Transplantation* 46:468-472, 1992.
3. **Alloway RR**, Kotb M, Hathaway DK, Gaber LW, Vera SR, Gaber AO. Low Dose OKT3 Induction Therapy of Cadaveric Transplant Recipients. *Scientia*, Volume 1, Issue 6, 1992.
4. Self T, Heilker G, **Alloway RR**, Kelso T, Abou-Shala N. Reassessing the Therapeutic Range for Theophylline on Laboratory Report Forms: The Importance of 5-15mcg/ml. *Pharmacotherapy* 13(6):590-594, 1993.
5. **Alloway RR**, Kotb M, Hathaway DK, Gaber LW, Vera SR, Gaber AO. Results of a Prospective, Randomized Double-Blind Study Comparing Standard Versus Low Dose OKT3 Induction Therapy. *Transplant Proc* 25(1):550-552, 1993.
6. **Alloway RR**, Kotb M, Hathaway DK, Gaber LW, Vera SR, Gaber AO. Results of a Prospective, Randomized Double-Blind Study Comparing Standard Versus Low Dose OKT3 Induction Therapy. *American Journal of Kidney Diseases* 22: 36-43, 1993.
7. Self T, **Alloway RR**. Nonsedating Antihistamines, *Pharmacy Newsletter*, September 1993.
8. **Alloway RR**, Spotlight of Heparin Dosing. *Drug Information Update*, Allied Pharmacy Management Inc. January 1994
9. **Alloway RR**, Kotb M, Hathaway D, Ohman M, Gaber AO. Pharmacokinetic Profile of OKT3 in Renal Transplant Recipients Receiving Standard and Low Dose OKT3 for Induction Immunosuppression.", *Transplantation* 58: 249-53, 1994.
10. Gaber LW, Moore LW, **Alloway RR**, Shokouh-Amiri MH, Vera SR, Gaber AO. Glomerulosclerosis as a determinant of post-transplant function of older donor renal allografts. *Transplantation* 60: 334-339, 1995.
11. Gaber LW, Moore LW, **Alloway RR**, Flax S, Gaber AO. Correlation between Banff classification, acute renal rejection scores, and reversal of rejection. *Transplant Proc* 27: 1019, 1995.
12. Nymann T, Shokouh-Amiri MH, Vera SR, Riely CA, **Alloway RR**, Gaber AO. Prevention of hepatitis B recurrence with indefinite hepatitis B immune globulin (HBIG) prophylaxis after liver transplantation. *Clin Transplantation* 10:663-667, 1996.

13. Moore LW, **Alloway RR**, Smith SO, Acchiardio SR, Gaber AO. Clinical observations of metabolic changes occurring in renal transplant recipients receiving ketoconazole. *Transplantation* 61: 537-541, 1996.
14. Self T, **Alloway RR**. Treatment of Rhinitis, *J Am Acad Nurse Pract* 8: 135-144, 1996.
15. Gaber LW, Moore L, **Alloway RR**, Flax S, Schroeder T, Amiri H, Gaber AO. Correlation between BANFF scores of acute renal rejection scores and reversal of rejection. *Kidney Int*, 49, 481-497, 1996.
16. **Alloway RR**, Russell WC, Gaber LW, Amiri MH, Vera SR, Gaber AO. Conversion from Cyclosporine to tacrolimus in kidney, kidney/pancreas and pancreas alone transplant recipients: the Memphis Experience. *Transplant Proc* 28: 995-997, 1996
17. Elmer D, Nymann T, Hathaway D, **Alloway RR**, Gaber AO. Use of FK-506 immunosuppression in pancreas transplant. *J Transplant Coordination* 6: 122-127, 1996.
18. **Alloway RR**. Guidelines for Administration of Intravenous Medications to Pediatric Patients, Fifth Edition, 1996.
19. Gaber LW, Moore LW, Reed L, Russel W, **Alloway R**, Hathaway D, Shokough-Amiri MH, Gaber AO. Renal histology with varying FK 506 blood levels. *Transplant Proc* 29: 186, 1997.
20. **Alloway RR**, Johnson JA, Chaballa M, Russell W, Reed L, Hathaway DK, Amiri H, Vera SR, Gaber AO. Effect of gut metabolism on tacrolimus bioavailability in renal transplant recipients." *Transplantation*, submitted.
21. Chaballa M, **Alloway RR**, Kotb M, Hathaway DK, Gaber LW, Vera SR, Gaber AO. Five year followup of a prospective randomized double-blind study comparing standard versus low dose OKT3 induction therapy in renal allograft recipients. "Transplantation, submitted.
22. **Alloway RR**, Schroeder T, Russell W, Reddy K, Moore L, Burton M, Shah, Gaber AO. An open labeled single center bioequivalence comparison of Sandimmune and Neoral versus Sang-35 cyclosporine. *Transplantation*, submitted.
23. **Alloway RR**, Schroeder T, Russell W, Moore L, Burton M, Shah M, Gaber AO. Bioequivalence comparison of Sandimmune and Neoral versus Sang-35 cyclosporine in kidney transplant recipients. *J Am Soc Nephrol* 8: 672A.
24. Schroeder TJ, First R, **Alloway RR**, Gaber AO, Levy R, Berger-Moran H., Floch R, Pouletty P. A program to develop a cyclosporine formulation that is bioequivalent to Neoral. *Transplantation*, submitted.

25. Stratta, RJ, **Alloway RR**. Pancreas transplantation for diabetes mellitus: A guide to recipient selection and optimum immunosuppression. *BioDrugs* 10(5): 347-357, 1998.
26. Somerville T, Hurst G, **Alloway RR**, Gaber A, Shokouh-Amiri MH, Stratta R. Superior efficacy of oral gancyclovir over oral acyclovir for cytomegalovirus prophylaxis in kidney-pancreas and pancreas alone recipients. *Transplant Proc* 30: 1546-1548, 1998.
27. Hurst G, **Alloway RR**, Hathaway D, Somerville T, Hughes T, Gaber AO. Stabilization of bone mass after renal transplant with preemptive care. *Transplant Proc* 30: 1327-1328, 1998.
28. Hurst GC, Somerville KT, **Alloway RR**, Hathaway D, Moore LW, Gaber AO. Continued loss of bone density one year post kidney transplant despite preemptive therapy. *Transplantation* 65: 149, 1998.
29. Somerville T, Hurst G, **Alloway RR**, Gaber A, Shokouh-Amiri MH, Stratta R. Efficacy of oral gancyclovir for CMV prophylaxis in kidney/pancreas and pancreas alone recipients. *Transplantation* 65: 213, 1998.
30. **Alloway RR**, Canafax D, Schroeder T, Russell W, Moore L, Burton M, Shah M, Gaber AO. Bioequivalence of Sang-35 and Neoral for cyclosporine metabolites in stable renal transplant patients. *Transplantation* 65: 82, 1998.
31. Russell W, **Alloway RR**, Demirkan K, Stratta R, Gaber AO. Preliminary experience with troglitazone (Rezulin) in kidney and kidney/pancreas transplant recipients. *Transplantation* 65: 211, 1998.
32. Reddy KS, Stratta R, Shokouh-Amiri H, **Alloway RR**, Somerville T, Elmer D, Gaber AO. Simultaneous kidney-pancreas transplantation without antilymphocyte induction. *Transplantation* 65: 251, 1998.
33. Schroeder TJ, First MR, **Alloway RR**, Canafax DM, Gaber AO, Gaston R. A series of comparative trials between Sang-35 and other cyclosporine formulations in stable renal transplant patients. *Transplantation* 65: 142, 1998.
34. Somerville T, Reddy S, **Alloway RR**, Hurst G, Gaber AO, Shokouh-Amiri MH, Stratta R. Incidence and management of mycophenolate mofetil adverse effects in simultaneous kidney/pancreas transplant patients. *Transplantation* 65: 213, 1998.
35. Regan J, **Alloway RR**, Rossi, S, Campbell K, Buelow R, Lankford M, Gaber AO. Clinical monitoring of cyclosporine using capillary blood collected and dried onto a collection device (Cyclostat). *Transplantation* 65: 218, 1998.
36. First MR, **Alloway RR**, Schroeder TJ. Development of Sang-35: a cyclosporine formulation bioequivalent to Neoral. *Clin Transplantation* 12: 518-524, 1998.

37. **Alloway RR**, Van Fleet A, Schroeder TJ, Moore LW, Gaber AO. Comparative effects of Sang-35 cyclosporine versus Neoral on biochemical markers of toxicities and safety in stable renal transplant recipients. *J Am Soc Nephrol* 9:663A, 1998.
38. Meier-Kirsch HU, **Alloway RR**, Gaber AO, Canafax D, Kaplan B. A limited sampling strategy (LSS) to predict the Sang-35 area under the curve (AUC) in adult renal transplant recipients. *J Am Soc Nephrol* 9:668A, 1998.
39. **Alloway RR**, Van Fleet A, Schroeder TJ, Canafax DM, Moore LW, Shah MJ, Gaber AO. A clinical practice experience in the development of Sang-35, a new cyclosporine formulation. *J Am Soc Nephrol* 9:663A, 1998.
40. Winsett RP and the Posttransplant Quality of Life Intervention Study Group. Posttransplant quality of life: a decade of descriptive studies leading to practice interventions. *J Transplant Coordination*, 8: 236-240, 1998.
41. Abell TL, Horn J, Adl D, Self T, Soberman J, **Alloway RR**, Thompson L. Correlation of cisapride levels with EKG Changes: A pilot clinical observation. *Gastroenterology* 116: , 1999.
42. Gaston R, **Alloway RR**, Gaber AO, Schroeder TJ, Irish WD, Canafax DM, First MR. Pharmacokinetic and safety evaluation of SangCya vs Neoral or Sandimmune in stable retransplant recipients. *Transplant Proc* 31: 326-327, 1999.
43. **Alloway RR**, Somerville TK. Transplantation: Solid Organ. *Basic Bibliographies. Hospital Pharmacy* 34: 379, 1999.
44. **Alloway RR**, TK Somerville. Transplantation Immunosuppression. *Basic Bibliographies. Hospital Pharmacy* 34: 380, 1999.
45. Posttransplant Quality of Life Intervention Study Group, University of Tennessee, Memphis. Bridging the gap between research and clinical practice. *American Neph Nurses Assoc J* 26: 235-240, 1999.
46. Stratta RJ, Gaber AO, Shokough-Amiri MH, Reddy S, **Alloway RR**, Egidi MF, Grewal HP, Gaber LW, Hathaway DK. Evolution in Pancreas Transplantation Techniques: Simultaneous Kidney-Pancreas Transplantation Using Portal-Enteric Drainage Without Antilymphocyte Induction. *Ann Surg* 229: 701-712, 1999.
47. Stratta RJ, Gaber AO, Shoukoku-Amiri MH, Reddy S, Egidi MF, Grewal HP, Hathaway DK, Winsett RP, **Alloway RR**, Gaber LW, Britt LG. Experience with Portal-Enteric Pancreas Transplant at the University of Tennessee-Memphis. *Clinical Transplants 1998*, Cecka and Terasaki, Eds. Chapter 22, p 239-253.
48. Sollinger HW, Bruce D, Humar A, Sutherland DER, Light JA, Kaufman DB, Anderson TK, **Alloway RR**, Stratta RJ. Multicenter retrospective analysis of simultaneous kidney pancreas transplant recipients receiving daclizumab induction. *Transplantation* 67: pS269, 1999.

49. Egidi MF, Trofe J, Reed L, Gaber LW, **Alloway RR**, Shoukhouh-Amiri MF, Stratta RJ, Gaber AO. Risk factors for Polyoma Virus: A comparative analysis in kidney-pancreas and kidney transplants. *Transplantation* 67: pS222, 1999.
50. Trofe J, **Alloway RR**, Godkin J, Kano J, Stratta RJ, Gaber AO. Thymoglobulin for the prophylaxis or treatment of rejection in pancreas allograft recipients: Results of the US compassionate use experience. *Transplantation* 67: pS209, 1999.
51. Reddy KS, Stratta RJ, Shoukhouh-Amiri MH, **Alloway R**, Egidi MF, Gaber AO. Surgical complications after pancreas transplantation with portal-enteric drainage. *J Am Coll Surg* 189: 305-313, 1999.
52. BN Nguyen, **RR Alloway**, AO Gaber, JA Johnson. Relationship between cyclosporine and endothelin concentrations in renal transplant recipients. *Transplantation* 67: pS167, 1999.
53. Tuteja S, **Alloway RR**, Johnson JA, Gaber AO. Effect of gut metabolism on tacrolimus (FK-506) bioavailability in renal transplant recipients. *Transplantation* 67: pS159, 1999.
54. Lo A, **Alloway RR**, Trofe J, Amiri HS, Egidi MF, Grewal HP, Stratta RJ, Vera S, Gaber AO. Outcomes in solid organ transplant patients received granulocyte stimulating factor (G-CSF) for the management of neutropenia. *Transplantation* 67: pS99, 1999.
55. Trofe J, Reddy KS, Somerville TK, Egidi MF, Flax S, **Alloway RR**, Stratta RJ, Gaber AO. Erlichiosis after pancreas transplantation. *Transplantation* 67: pS98, 1999.
56. Gaber LW, Egidi MF, Sing V, Trofe J, **Alloway RR**, Kotb M, Gaber AO. Focal mild intimal arteritis without associated parenchymal inflammation: Rejection or no rejection. *Transplantation* 67: pS87, 1999.
57. Egidi MF, Trofe J, Stratta RJ, Shoukhouh-Amiri MH, Grewal HP, **Alloway RR**, Gaber AO. The Effect of Tacrolimus on the Blood Sugar Control in Pancreas Transplant Patients: A Comparison Among Systemic Enteric, Portal Enteric, and Bladder Anastomosis Techniques. American Society of Transplant Surgeons, May, 1999.
58. Schroeder TJ, First MR, **Alloway RR**, Pan SH, Gaber AO, Lopez RR, Fisher RA, Irish WD, Canafax DM, Pouletty P. Review of Cyclosporine Pharmacokinetic Trials in Healthy Volunteers and Kidney and Liver Transplant Recipients: SangCyA Versus Neoral and Sandimmune. *Transplantation Reviews* 13: 1-7, 1999.
59. **Alloway RR**. Generic immunosuppressant use in solid organ transplantation. *Transplant Proc* 31: 2S-5S, 1999.
60. Stratta RJ, Gaber AO, Shoukhouh-Amiri MH, Reddy KS, **Alloway RR**, Egidi MF, Grewal HP, Gaber LW, Hathaway D. Evolution in pancreas transplantation techniques: simultaneous kidney-pancreas transplantation using portal-enteric drainage without antilymphocyte induction. *Ann Surg* 229: 709-712, 1999.

61. Schroeder TJ, **Alloway RR**, First R, Moore LW, Pouletty P, Gaston R. Development of Sang-35: A cyclosporine formulation bioequivalent to Neoral. *Clinical Transplantation*, in press.
62. Reddy S, Stratta RJ, Shokouh-Amiri MH, **Alloway RR**, Somerville T, Egidi MF, Gaber AO. Simultaneous Kidney-Pancreas Transplantation Without Anti-lymphocyte Induction. *Transplantation* 69: 49-54, 2000.
63. **Alloway RR**, Schroeder T, Russell W, Reddy K, Moore L, Burton M, Shah, Gaber AO. "An open labeled single center bioequivalence comparison of Neoral versus Sang-35 cyclosporine." *Journal of the American Society of Nephrology*, accepted.
64. **Alloway RR**, Canafax D, Schroeder T, Russell W, Moore L, Burton M, Shah M, Gaber AO. "Bioequivalence of Sang-35 and Neoral for cyclosporine metabolites in stable renal transplant patients." *Clinical Transplantation*, accepted.
65. Hurst GC, **Alloway RR**, Somerville KT, Gaber AO, Stratta RJ. Preliminary experience with midodrine in kidney/pancreas transplant patients with orthostatic hypotension. *Clin Transplant* 14:42-47, 2000.
66. Hurst GC, Somerville KT, **Alloway RR**, Hathaway D, Moore LW, Gaber AO. Continued loss of bone density one year post kidney transplant despite preemptive therapy. *Clin Transplantation*, submitted.
67. Meier-Kriesch HU, **Alloway RR**, Gaber AO, Canafax D, Kaplan B. A limited sampling strategy (LSS) for the estimation of 12-hour SangCya and Neoral AUCs in Renal Transplant Recipients. *J Clin Pharmacol.* 39: 166-17, 1999.
68. Trofe J, Stratta RJ, Gaber LW, Shoukhou-Amiri MH, Lo A, **Alloway RR**, Gaber AO, Egidi MF. Fatal Hemolytic Uremic Syndrome in a Simultaneous Kidney-Pancreas Transplant Patient Receiving Daclizumab, Tacrolimus, Mycophenolate Mofetil, and Steroids. Submitted to *Transplantation*., April 2000.
69. Trofe J, Reddy KS, Stratta RJ, Flax SD, Somerville KT, **Alloway RR**, Egidi MF, Shokouh-Amiri MH, Gaber AO. Human Granulocytic Ehrlichiosis in Pancreas Transplant Recipients. Submitted to *Transplant Infectious Disease*. April 2000.
70. MF Egidi, J Trofe, RJ Stratta, SD Flax, LW Gaber, HS Amiri, M Jones, NA Khan, SR Vera, HP Grewal, **RR Alloway**, AO Gaber. Post transplant lymphoproliferative disorders: therapeutic approach and outcome in solid organ transplantation. Accepted to *Transplant Proceedings* May 2000.
71. MR First, **RR Alloway**, RA Fisher, SH Pan, R Lopez, D Renlund, M Schnitzler AO Gaber, Generic Drug Substitution in Transplantation: Examples from the Epic of Cyclosporine Development. *Dialysis and Transplantation*, Vol 29, Number 5, 260-267, May 2000.

## 72. The effect of gut metabolism....

73. A Lo, RJ Stratta, MF Egidi, MH Shokouh-Amiri, **et al.** Outcomes of simultaneous kidney-pancreas transplantation in African-American recipients: A case control study. *Clinical Transplantation* (In press 2000).
74. A Lo, RJ Stratta, MF Egidi, MH Shokouh-Amiri, **et al.** Patterns of cytomegalovirus infection in simultaneous kidney-pancreas transplant recipients receiving tacrolimus, mycophenolate mofetil, and prednisone with ganciclovir prophylaxis. *Transplant Infectious Diseases* (In press 2000).
75. RJ Stratta, **RR Alloway**, A Lo, E Hodge for the PIVOT study group. An Open-Labeled, Comparative Trial of Two Daclizumab Dosing Strategies versus No Induction Treatment in combination with Tacrolimus, Mycophenolate Mofetil, and Steroids for the Prevention of Acute Rejection in Simultaneous Kidney/Pancreas Transplant Recipients: 3 months interim analysis. Submitted to *Transplantation* (September 2000).
76. A Lo, RJ Stratta, DK Hathaway, **et al.** Long-term outcomes in simultaneous kidney-pancreas transplant recipients with portal-enteric vs. systemic-bladder drainage. Submitted to *American Journal of Kidney Disease* (August 2000).
77. KL Hardinger, MH Shokouh-Amiri, A Lo, HP Grewal, S Vera, RJ Stratta, MF Egidi, MR Honaker, AT Kizilisik, **RR Alloway**, AO Gaber. A comparison of low-dose, short course mycophenolate mofetil and tacrolimus versus full-dose, long course mycophenolate mofetil and cyclosporine after liver transplantation. Submitted (*Transplantation* July 2000).
78. A Lo, RJ Stratta, J Trofe, J Norwood, MF Egidi, MH Shokouh-Amiri, HP Grewal, **Rita R Alloway**, AO Gaber. Rhodococcus Equi Pulmonary Infection in a Pancreas Alone Transplant Recipient: Consequence of Intense Immunosuppression. Submitted *Transplant Infectious Disease* (June 2000).
79. DS Bruce, HW Sollinger, A Humar, DER Sutherland, JA Light, DB Kaufman, **RR Alloway**, A Lo, RJ Stratta. Multicenter Survey of Daclizumab Induction in Simultaneous Kidney-Pancreas Transplant Recipients. Submitted *Transplantation* (June 2000).
80. A Lo, RJ Stratta, MF Egidi, MH Shokouh-Amiri, **et al.** Limited benefits of induction with monoclonal antibody to interleukin-2 receptor in simultaneous kidney-pancreas transplantation. Submitted to *Transplant International* (June 2000).
81. J Trofe, RJ Stratta, LW Gaber, Shokouh-Amir MH, A Lo, **RR Alloway**, AO Gaber, MF Egidi. Fatal hemolytic uremic syndrome in a simultaneous kidney-pancreas transplant patient receiving daclizumab, tacrolimus, mycophenolate mofetil, and steroids. Submitted *Transplantation* (April 2000).
82. Trofe, J. , Stratta RJ, Gaber LW, Amiri MHS, Grewal HP, Vera SR, Lo, A, Alloway RR, AO Gaber, MF Egidi. Polyomavirus: A Comparative Analysis in Kidney and

Kidney Pancreas Transplants and Identification of Associated Factors. Submitted to Transplant Infectious Diseases.

83. Egidi MF, Trofe J, Stratta RJ, Flax SD, Gaber LW, Shokouh-Amiri MH, Jones M, Vera SR, Grewal HP, Alloway RR, Gaber AO. Post Transplant Lymphoproliferative Disorders: Single Center Experience. Accepted to Transplant Proceedings August 2000.
84. Kizilisik TA, Lo A, Stratta RJ, Egidi MF, Amiri MH, Grewal HP, Alloway RR, Trofe J, Gaber AO. Ganciclovir Prophylaxis for CMV Infection in Simultaneous Kidney Pancreas Transplant Recipients Receiving Tacrolimus, Mycophenolate Mofetil, and Prednisone. Accepted to Transplant Proceedings August 2000.

**ABSTRACTS**

1. Winsett RP, Hathaway DK, **Alloway RR**, Gaber AO. Effective and Safe Use of Ketoconazole as Adjunctive Immunosuppressive Therapy. North American Transplant Coordinators Organization, April 1991.
2. Gaber AO, Kotb M, Winsett RP, Gaber LW, Vera SR, Phillips D, Boskey FD, **Alloway RR**. Standard Versus Low Dose OKT3 Induction: Comparison of Immune Monitoring Data and Results. Proceedings of the American Society of Transplant Physicians (1-32) p. 186, 1991.
3. Gaber L, Vera S, Hathaway D, Salem A, **Alloway RR**, Gaber AO. Routine Biopsy and Induction Therapy Affect Outcome of Delayed Graft Function., National Kidney Foundation, November, 1992.
4. Gaber L, Vera S, Hathaway D, Salem A, **Alloway RR**, Gaber AO. Routine Biopsy and Induction Therapy Affect Outcome of Delayed Graft Function. American Society of Nephrologists/National Kidney Foundation, November 1993.
5. Gaber L, Moore L, **Alloway RR**, Flax S, Gaber AO. Correlation Between BANFF Classification, Acute Renal Rejection Scores and Reversal of Rejection. American Society of Transplantation Physicians, January, 1994.
6. **Alloway RR**, Kotb M, Hathaway D, Schroeder T, Gaber AO. Demographic and clinical factors effecting TCR expression during and following OKT3 treatment. The American Society of Nephrology, October 1994
7. Moore LW, **Alloway RR**, Smith SO, Acchiardio SR, Gaber AO. Ketoconazole enhances loss of bone in renal transplant recipients. American Society of Transplantation Physicians Annual Meeting, Chicago, Illinois, May 1995.
8. Rageuh I, Kotb M, Fraga D, Schroeder T, Chan F, Russell WC, **Alloway RR**, Gaber AO. A comparison of methodologies used for measurement of circulating OKT3 levels. American Society of Transplantation Physicians Annual Meeting, Chicago, Illinois May 1995.
9. Gaber LW, Moore L, **Alloway RR**, Flax S, Schroeder T, Amiri H, Gaber AO. Correlation between BANFF scores of acute renal rejection scores and reversal of rejection. American Society of Transplantation Physicians Annual Meeting, Chicago, Illinois, May 1995.
10. Gaber LW, Moore LW, **Alloway RR**, Shokouh-Amiri MH, Vera SR, Gaber AO. Glomerulosclerosis as a determinant of post-transplant function of older donor renal allografts. American Society of Transplantation Physicians Annual Meeting, Chicago, Illinois, May 1995.

11. **Alloway RR**, Russell WC, Gaber LW, Amiri MH, Vera SR, Gaber AO. Conversion from cyclosporine to FK-506 in kidney, kidney/pancreas and pancreas alone transplant recipients. A single center experience. Minneapolis Transplant Congress: New Immunosuppressive Drugs, Minneapolis, Minnesota, August 1995.
12. Elmer D, Nymann T, Hathaway D, **Alloway RR**, Gaber AO. Use of FK-506 –based immunosuppression in pancreas transplantation. National Association of Transplant Coordinators Organization Annual Meeting, Boston, Massachusetts, August 1995.
13. Trine Nymann, Vera SR, Amiri MH, Riely C, **Alloway RR**, Gaber AO. Prevention of Hepatitis B recurrence with indefinite immunoprophylaxis after liver transplantation. South Eastern Organ Procurement Foundation Tri-Annual Meeting, Orlando Florida, January 1996.
14. Gaber LW, Moore LW, Russell W, **Alloway RR**, AO Gaber. Donor glomerulosclerosis impacts both short and long-term renal allograft function. American Society of Transplantation Physicians Annual Meeting, Dallas, TX, May 1996.
15. Mendez R, Noriega A, Lowance D, **Alloway RR**, Lee I, Coggon G. Valaciclovir reduces the incidence of CMV disease in CMV-seropositive cadaveric renal allograft recipients. Sixth International Cytomegalovirus Workshop, Minneapolis, Minnesota, March 1997.
16. **Alloway RR**, Johnson JA, Chaballa M, Russell W, Reed L, Hathaway DK, Amiri H, Vera SR, Gaber AO. Effect of gut metabolism on tacrolimus bioavailability in renal transplant recipients. American Society of Transplantation Surgeons Annual Meeting, Chicago IL, May 1997.
17. Chaballa M, **Alloway RR**, Kotb M, Hathaway DK, Gaber LW, Vera SR, Gaber AO. Five year followup of a prospective randomized double-blind study comparing standard versus low dose OKT3 induction therapy in renal allograft recipients. American Society of Transplantation Physicians Annual Meeting, Chicago Illinois, May 1997.
18. **Alloway RR**, Schroeder T, Russell W, Reddy K, Moore L, Burton M, Shah, Gaber AO. An open labeled single center bioequivalence comparison of Sandimmune and Neoral versus Sang-35 cyclosporine. American Society of Transplantation Physicians Annual Meeting, Chicago IL, May 1997.
19. Schroeder TJ, First R, **Alloway RR**, Gaber AO, Levy R, Berger-Moran H., Floch R, Pouletty P. A program to develop a cyclosporine formulation that is bioequivalent to Neoral. American Society of Transplantation Physicians Annual Meeting, Chicago IL, May 1997.
20. Neumayer H, Valaciclovir International Renal Transplant Study Group. Efficacy and safety of valaciclovir for suppression of cytomegalovirus disease in recipients of a cadaveric renal allograft. Thirty-Seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, October, 1997.

21. Hurst GC, **Alloway RR**, Somerville KT, Gaber AO, Stratta RJ. Preliminary experience with midodrine in kidney/pancreas transplant patients experiencing orthostatic hypotension. American Society of Transplant Physicians Annual Meeting, Chicago, Illinois, May, 1998.
22. Hurst GC, Somerville KT, **Alloway RR**, Hathaway D, Moore LW, Gaber AO. Continued loss of bone density one year post kidney transplant despite preemptive therapy. American Society of Transplant Physicians Annual Meeting, Chicago Illinois, May 1998.
23. **Alloway RR**, Canafax D, Schroeder T, Russell W, Moore L, Burton M, Shah M, Gaber AO. Bioequivalence of Sang-35 and Neoral for cyclosporine metabolites in stable renal transplant patients. American Society of Transplant Physicians Annual Meeting, Chicago, Illinois, May, 1998.
24. Regan J, **Alloway RR**, Rossi S, Campbell K, Buelow R, Lankford M, Gaber AO. Clinical monitoring of cyclosporine: Capillary whole blood collected with the cyclostat collection device. XVII World Congress of the International Transplant Society, Montreal Canada, July 1998.
25. Gaber AO, Shoukhouh-Amiri, Stratta RJ, Reddy KS, **Alloway RR**, Britt LG, Evolution in pancreas transplantation techniques: simultaneous kidney-pancreas transplantation using portal-enteric drainage without antilymphocyte induction. Southern Surgical Association Annual Meeting, December 1998.
26. Abell TL, Horn J, Adl D, Self T, Soberman J, **Alloway RR**, Thompson L. Correlation of cisapride levels with EKG Changes: A pilot clinical observation. 1999 Spring Digestive Diseases Week Meeting of the American Gastroenterology Association, April 1999.
27. Sollinger HW, Bruce D, Humar A, Sutherland DER, Light JA, Kaufman DB, Anderson TK, **Alloway RR**, Stratta RJ. Multicenter retrospective analysis of simultaneous kidney pancreas transplant recipients receiving daclizumab induction. 18<sup>th</sup> Annual Meeting of the American Society of Transplantation., Chicago Illinois. May 1999.
28. Egidi MF, Trofe J, Reed L, Gaber LW, **Alloway RR**, Shoukhouh-Amiri MH, Stratta RJ, Gaber AO. Risk factors for polyoma virus: A comparative analysis in kidney-pancreas and kidney transplants. 18<sup>th</sup> Annual Meeting of the American Society of Transplantation, Chicago Illinois. May 1999.
29. Trofe J, **Alloway RR**, Godkin J, Kano J, Stratta RJ, Gaber AO. Thymoglobulin for the prophylaxis or treatment of rejection in pancreas allograft recipients: Results of the US compassionate use experience. 18<sup>th</sup> Annual Meeting of the American Society of Transplantation, Chicago Illinois, May, 1999.
30. Stratta RJ, Shoukhouh-Amiri MH, Egidi MF, Grewal HP, Gaber LW, **Alloway RR**, Hathaway DK, Reddy KS, Gaber AO. Graft failure after solitary pancreas

transplantation. 7<sup>th</sup> World Congress of the International Pancreas and Islet Transplant Association, Sydney, Australia, August 1999.

31. Stratta RJ, Shokouh-Amiri MH, Egidi MF, Grewal HP, Gaber LW, **Alloway RR**, Hathaway DK, Reddy KS, Gaber AO. Patterns of graft loss after simultaneous kidney-pancreas transplantation according to technique and immunosuppressive era. 7<sup>th</sup> World Congress of the International Pancreas and Islet Transplant Association. Oral presentation, Sydney, Australia, August 1999.
32. Stratta RJ, Gaber AO, Shokouh-Amiri MH, Egidi MF, Grewal HP, Gaber LW, **Alloway RR**, Hathaway DK, Reddy KS. A single center experience with 108 cases of pancreas transplantation with portal-enteric drainage. 7<sup>th</sup> World Congress of the International Pancreas and Islet Transplant Association. Oral presentation, Sydney, Australia, August 1999.
33. Sollinger HW, Bruce DS, Humar A, Sutherland DER, Light JA, Kaufman DB, Anderson TK, **Alloway RR**, Stratta RJ. Multicenter analysis of daclizumab induction in simultaneous kidney pancreas transplant recipients. 7<sup>th</sup> World Congress of the International Pancreas and Islet Transplant Association, Sydney, Australia, August 1999.
34. RJ Stratta, **RR Alloway**, E Hodge for the PIVOT study group. An open-label, comparative trial of two daclizumab dosing strategies versus no antibody induction combined with tacrolimus, mycophenolate mofetil, and steroids for the prevention of acute rejection in simultaneous kidney/pancreas recipients: Interim analysis. First Joint Annual Meeting of the American Society of Transplant Surgeons and the American Society of Transplantation. Chicago IL. May 2000.
35. LW Gaber, A Lo, MF Egidi, RJ Stratta, MH Amiri, HP Grewal, T Kizilisik, **RR Alloway**, AO. Gaber. Relationship of histological and clinical features of first acute rejection on recurrent rejection and pancreas failure. First Joint Annual Meeting of the American Society of Transplant Surgeons and the American Society of Transplantation. Chicago IL. May 2000.
36. Egidi MF, Trofe J, Stratta RJ, Flax SD, Gaber LW, Shokouh-Amiri MH, Jones M, Vera SR, Grewal HP, **Alloway RR**, Gaber AO. Post Transplant Lymphoproliferative Disorders: Single Center Experience. Accepted as an oral presentation to the 18<sup>th</sup> International Congress of the Transplantation Society, August 27-September 1, 2000.
37. Kizilisik TA, Lo A, Stratta RJ, Egidi MF, Amiri MH, Grewal HP, **Alloway RR**, Trofe J, Gaber AO. Ganciclovir Prophylaxis for CMV Infection in Simultaneous Kidney Pancreas Transplant Recipients Receiving Tacrolimus, Mycophenolate Mofetil, and Prednisone. Accepted as an oral presentation to the 18<sup>th</sup> International Congress of the Transplantation Society, August 27-September 1, 2000.
38. Shokouh-Amiri MH, Egidi MF, Lo A, Grewal HP, Vera SR, Stratta RJ, Khan NA, Trofe J, **Alloway RR**, Gaber AO. The Importance of Early Prevention of Renal Dysfunction in Liver Transplant Recipients. Accepted as poster presentation to the 18<sup>th</sup> International Congress of the Transplantation Society, August 27-September 1, 2000.

39. Hanaway MJ, Trofe J, Buell JF, Lo A, **Alloway RR**, Beebe T, Woodle ES. Colon Cancer Risk in Liver Transplant Recipients: The Israel Penn International Transplant Tumor Registry Experience. Accepted as an oral presentation to *Transplantation 2001*: Chicago, Illinois.
40. Trofe J, Buell JF, Hanaway M, Beebe T, First MR, **Alloway RR**, Lo A, Rilo H, Woodle ES. Post-Transplant Lymphoproliferative Disorder in Kidney Transplantation: A 32-Year Experience in 405 Patients from the Israel Penn Transplant Tumor Registry. Accepted as an oral presentation to *Transplantation 2001*: Chicago, Illinois. *Recipient of a Young Investigator Award*
41. Stratta RJ, **Alloway RR**, Lo A, Hodge E A. MultiCenter Open-Label Comparative Trial of 2 Daclizumab Dosing Strategies VS no Antibody induction in combination with Tacrolimus, Mycophenolate Mofetil, and Steroids in Simultaneous Kidney-Pancreas Transplantation: 6 Month Analysis. Accepted as an oral presentation to *Transplantation 2001*: Chicago, Illinois
42. Hardinger KL, Stratta RJ, Egidi, MF, **Alloway RR**, Amiri MH, Gaber LW, Grewal HP, Honaker MR, Vera SR, Gaber AO Renal Allograf Outcomes in African American Versus Caucasian Transplant Recipients in the Tacrolimus Era. Accepted as a poster presentation to *Transplantation 2001*: Chicago, Illinois
43. Trofe J, Stratta RJ, Lo A, Gaber LW, Amiri HS, Grewal HP, Egidi MF, Honaker M, Hardinger K, **Alloway RR**, Gaber AO. Thymoglobulin for induction or rejection therapy in pancreas allograft recipients-single center experience. Accepted as a poster presentation to *Transplantation 2001*: Chicago, Illinois
44. RJ Stratta, AO Gaber, MH Shokouh-Amiri, HP Grewal, MF Egidi, AT Kizilisik, DK Hathaway, **RR Alloway**, LW Gaber. A 9-year Experience with 125 Pancreas Transplants with Portal-Enteric Drainage. Accepted as an oral presentation to the 2000 Western Surgical Association, November 13, 2000.
45. Donor Transmission of a renal cell carcinoma from a living related donor to a kidney recipient. TM Beebe, JF Buell, **RR Alloway**, MJ Hanaway, MR First, ES Woodle. International Transplant Nurses Society, 2001.
46. Maltoma: infectious etiology of malignancy in transplant patients. MJ Aull, J Trofe, MR First, M Hanaway, TM Beebe, **RR Alloway**, ES Woodle, JF Buell. . International Transplant Nurses Society, 2001

**POSTERS**

1. Kelso TM, Self TH, **Alloway RR**. Cost Benefit of Conversion from Nebulized Therapy to MDI plus Spacer, 1992 Winter Practice and Research Forum of the American College of Clinical Pharmacy, February 1992.
2. Kelso TM, Self TH, **Alloway RR**. Cost Benefit of Conversion from Nebulized Therapy to MDI plus Spacer, Tennessee Thoracic Society Annual Meeting, April 1992.
3. **Alloway RR**, Kotb M, Hathaway DK, Vera SR, Britt L, Gaber AO. Low Dose OKT3 Induction Therapy of Cadaveric Transplant Recipients. International Congress of the Transplantation Society, August 1992.
4. **Alloway RR**, Kotb M, Hathaway DK, Gaber LW, Vera SR, Gaber AO. Results of a Prospective, Randomized Double-Blind Study Comparing Standard Versus Low Dose OKT3 Induction Therapy. American Society of Transplant Surgeons, May 1992.
5. Kotb M, Hathaway DK, **Alloway RR**, Gaber LW, Docktor M, Vera SR, Gaber AO. Evaluation of Immunological Markers Predictive of Successful OKT3 Induction. American Society of Transplant Physicians Annual Meeting, May 1993.
6. **Alloway RR**, Kotb M, Hathaway D, Ohman M, Strain S, Gaber AO. Pharmacokinetic Profile of OKT3 in Renal Transplant Recipients Receiving Standard and Low Dose OKT3 for Induction Immunosuppression., American Society of Transplant Physicians, May 1993.
7. Ohman M, Kotb M, Leathers LK, Hathaway DK, **Alloway RR**, Gaber LW, Gaber AO. Multiparameter Monitoring of Efficacy of OKT3-Induced Immune Suppression in Renal Allograft Recipients. 19th Annual Meeting of the American Society of Histocompatibility and Immunogenetics, San Francisco, California, August 1993.
8. Lomas R, Kuns J, Kumar A, **Alloway RR**, Abell TL. Patient Controlled Promethazine Infusion for Symptom Control in Intractable Nausea and Vomiting. American Gastroenterological Association/American Association for the Study of Liver Diseases, May 1993.
9. Gaber L, Moore L, **Alloway RR**, Flax S, Gaber AO. Clinical Applicability of the BANFF Classification for Acute Renal Rejection. 26th Annual Meeting of The American Society of Nephrology, November 1993.
10. Gaber L, Moore L, **Alloway RR**, Amiri H, Gaber AO. Influence of Donor Nephrosclerosis (ANS) on Kidney Allograft Function. 26th Annual Meeting of The American Society of Nephrology, November 1993.

11. Lomas R, Kuns J, Kumar A, **Alloway RR**, Voeller G, Abell TL. One Year Follow Up of Patients Treated with Patient Controlled Promethazine for Intractable Nausea. American Gastroenterological Association/American Association for the Study of Liver Diseases, May 1994.
12. Evans SL, **Alloway RR**, Vera S, Horvath J, Hathaway DK, Gaber AO. The clinical of CMV titers and cultures in the clinical management of transplant patients. American Society of Transplantation Physicians Annual Meeting, May 1995.
13. Anderson RN, Sherman J, **Alloway RR**, Solomon SS. Effect of cyclosporine and FK506 on insulin actions in H-411E cells. American Society of Transplantation Physicians, Chicago IL, May 1997.
14. **Alloway RR**, Schroeder T, Russell W, Reddy K, Moore L, Burton M, Shah, Gaber AO. Bioequivalence comparison of Sandimmune and Neoral versus Sang-35 cyclosporine in kidney transplant recipients. 1997 Annual Scientific Meeting of the American Society of Nephrology, San Antonio, Texas, November 1997.
15. Somerville T, Hurst G, **Alloway RR**, Shokouh-Amiri MH, Gaber A, Stratta R. Superior efficacy of oral ganciclovir over oral acyclovir for CMV prophylaxis in kidney/pancreas and pancreas alone recipients. Seventh International Congress on Immunosuppression, Orlando Florida, December 1997.
16. Chaballa M, **Alloway RR**, Kotb, M, Hathaway DK, Gaber L, Vera SR, Gaber AO. Five year followup of a prospective, randomized double-blind study comparing standard versus low dose OKT3 induction therapy in renal allograft recipients. Seventh International Congress on Immunosuppression, Orlando Florida, December 1997.
17. Hurst G, **Alloway RR**, Hathaway D, Somerville T, Moore L, Gaber A. Stabilization of bone mass post renal transplant with preemptive care. Seventh International Congress on Immunosuppression, Orlando Florida, December 1997.
18. Alak AM, Moy S, **Alloway RR**, Fraga D, Kotb M, Gaber AO. Tacrolimus concentrations in renal transplant patients: correlation between levels determined by Abbott Imx and HPLC coupled with mass spectrometer. Seventh International Congress on Immunosuppression, Orlando Florida, December 1997.
19. **Alloway RR**, Schroeder T, Russell W, Reddy K, Moore L, Burton M, Shah, Gaber AO. A bioequivalence cross-over study of comparison of Sang-35 cyclosporine versus Sandimmune and Neoral in kidney transplant patients. Eighth Congress of the European Society for Organ Transplantation, Budapest, Hungary, September 1997.
20. Somerville T, Hurst G, **Alloway RR**, Gaber A, Shokouh-Amiri MH, Stratta R. Efficacy of oral ganciclovir for CMV prophylaxis in kidney/pancreas and pancreas

alone recipients. American Society of Transplant Physicians, Chicago Illinois, May 1998.

21. Russell W, **Alloway RR**, Demirkan K, Stratta R, Gaber AO. Preliminary experience with troglitazone (Rezulin) in kidney and kidney/pancreas transplant recipients. American Society of Transplant Physicians, Chicago Illinois, May 1998.
22. Reddy KS, Stratta R, Shokouh-Amiri H, **Alloway RR**, Somerville T, Elmer D, Gaber AO. Simultaneous kidney-pancreas transplantation without antilymphocyte induction. American Society of Transplant Physicians, Chicago Illinois, May 1998.
23. Schroeder TJ, First MR, **Alloway RR**, Canafax DM, Gaber AO, Gaston R. A series of comparative trials between Sang-35 and other cyclosporine formulations in stable renal transplant patients. American Society of Transplant Physicians, Chicago Illinois, May 1998.
24. Somerville T, Reddy S, **Alloway RR**, Hurst G, Gaber AO, Shokouh-Amiri MH, Stratta R. Incidence and management of mycophenolate mofetil adverse effects in simultaneous kidney/pancreas transplant patients. American Society of Transplant Physicians, Chicago Illinois, May 1998.
25. Regan J, **Alloway RR**, Rossi, S, Campbell K, Buelow R, Lankford M, Gaber AO. Clinical monitoring of cyclosporine using capillary blood collected and dried onto a collection device (Cyclostat). American Society of Transplant Physicians, Chicago Illinois, May 1998.
26. Reddy KS, Stratta R, Shokouh-Amiri MH, **Alloway RR**, Somerville T, Elmer D, Gaber A. Simultaneous Kidney-pancreas transplantation without antilymphocyte induction. XVII World Congress, Montreal Canada, July 1998.
27. Somerville T, Reddy S, **Alloway RR**, Hurst G, Gaber AO, Shokouh-Amiri MH, Stratta R. Incidence and management of mycophenolate mofetil adverse effects in simultaneous kidney/pancreas transplant patients. XVII World Congress, Montreal Canada, July 1998.
28. Schroeder T, First R, **Alloway RR**, Pan SH, Gaber AO. Pharmacokinetic trials in normals, kidney, and liver transplant patients: Sang-35 vs. Neoral cyclosporine. XVII World Congress of the International Transplant Society, Montreal Canada, July 1998.
29. Gaston R, First MR, **Alloway RR**, Canafax DM, Gaber AO, Schroeder TJ. Sang-35 vs. Neoral or Sandimmune in stable renal transplant patients. XVII World Congress, Montreal Canada, July 1998.
30. Meier-Kriesch HU, **Alloway RR**, Gaber AO, Canafax D, Kaplan B. A limited sampling strategy (LSS) to predict the Sang-35 area under the curve (AUC) in adult renal transplant recipients. 31<sup>st</sup>. Annual Meeting and Scientific Exposition of the American Society of Nephrology, Philadelphia Pennsylvania, October 1998.

31. **Alloway RR**, VanFleet A, Schroeder TJ, Canafax DM, Moore LW, Shah MJ, Gaber AO. A clinical practice experience in the development of Sang-35, a new cyclosporine formulation. 31<sup>st</sup>. Annual Meeting and Scientific Exposition of the American Society of Nephrology, Philadelphia Pennsylvania, October 1998.
32. Reddy KS, Stratta RJ, **Alloway RR**, Somerville TK, Amiri HS, Gaber AO. Innovations in Pancreas Transplantation: Simultaneous kidney-pancreas transplant using portal-enteric drainage without anti-lymphocyte induction. 31<sup>st</sup>. Annual meeting and scientific exposition. American Society of Nephrology, Philadelphia Pennsylvania, October 1998.
33. Tuteja S, **Alloway RR**, Johnson JA, Gaber AO. Effect of gut metabolism on tacrolimus (FK-506) bioavailability in renal transplant recipients. 18<sup>th</sup> Annual Meeting of the American Society of Transplantation, Chicago Illinois, May 1999.
34. Lo A, **Alloway RR**, Trofe J, Amiri HS, Egidi MF, Grewal HP, Stratta RJ, Vera S, Gaber AO. Outcomes in solid organ transplant patients received granulocyte stimulating factor (G-CSF) for the management of neutropenia. 18<sup>th</sup> annual meeting of the American Society of Transplantation. Chicago IL. May 1999.
35. Trofe J, Reddy KS, Somerville TK, Egidi MF, Flax M, **Alloway RR**, Stratta RJ, Gaber AO. Erlichiosis after pancreas transplantation. Eighteenth Annual Meeting of the American Society of Transplantation, Chicago Illinois, May, 1999.
36. LW Gaber, MF Egidi, V Sing, J Trofe, **R Alloway**, M Kotb, AO Gaber. Focal mild intimal arteritis without associated parenchymal inflammation: Rejection or No Rejection. 18<sup>th</sup> annual meeting of the American Society of Transplantation. Poster presentation, Chicago IL. May 1999.
37. RJ Stratta, A Lo, DK Hathaway RP Winsett, EF Egidi, MH Shoukouch-Amiri, HP Grewal, **RR Alloway**, AO Gaber. Long-term outcomes in simultaneous kidney-pancreas transplant recipients with portal-enteric drainage. 25<sup>th</sup> annual meeting of the American Society of Transplant Surgeons. Poster presentation, Chicago IL. May 1999.
38. MF Egidi, J Trofe, RJ Stratta, MH Shoukouch-Amiri, HP Grewal, **RR Alloway**, AO Gaber. The effect of tacrolimus on the blood sugar control in pancreas transplant patients: A comparison among systemic enteric, portal enteric, and bladder Anastomosis techniques. 25<sup>th</sup> annual meeting of the American Society of Transplant Surgeons. Poster presentation, Chicago IL. May 1999.
39. BN Nguyen, **RR Alloway**, AO Gaber, JA Johnson. Relationship between cyclosporine and endothelin concentrations in renal transplant recipients. 18<sup>th</sup> annual meeting of the American Society of Transplantation. Poster presentation, Chicago IL. May 1999.

40. Stratta RJ, Egidi MF, Shokouh-Amiri MH, Grewal HP, Hathaway DK, **Alloway RR**, Gaber AO. Analysis of mortality after pancreas transplantation according to transplant type and immunosuppressive era. 7<sup>th</sup> World Congress of the International Pancreas and Islet Transplant Association, Sydney, Australia, August 1999.
41. Stratta RJ, Lo A, Hathaway DK, Winsett RP, Egidi MF, Shokouh-Amiri MH, Grewal HP, **Alloway RR**, Gaber AO. Long-term outcome in simultaneous kidney-pancreas transplant recipients with portal-enteric drainage. Seventh World Congress of the International Pancreas and Islet Transplant Association, Sydney, Australia, August 1999.
42. Stratta RJ, Lo A, Hathaway DK, Winsett RP, Egidi MF, Shokouh-Amiri H, Grewal HP, **Alloway RR**, Gaber AO. Is the native pancreas more susceptible to abnormalities causing glucose intolerance than the transplanted pancreas? Seventh World Congress of the International Pancreas and Islet Transplant Association, Sydney, Australia, August 1999.
43. Egidi MF, Trofe J, Stratta RJ, Shokouh-Amiri MH, **Alloway RR**, Grewal HP, Gaber AO. Glucose control in pancreas transplants: Comparative study among anastomotic techniques. Seventh World Congress of the International Pancreas and Islet Transplant Association, Sydney, Australia, August 1999.
44. Trofe J, **Alloway R**, Godkin J, Kano J, Stratta R, Gaber A. Thymoglobulin use in pancreas transplantation. Seventh World Congress of the International Pancreas and Islet Transplant Association, Sydney, Australia, August 1999.
45. Trofe J, Reddy KS, Somerville TK, Egidi MF, Flax S, **Alloway RR**, Stratta RJ, Gaber AO. Erlichiosis infection in pancreas transplants. Seventh World Congress of the International Pancreas and Islet Transplant Association, Sydney, Australia, August 1999.
46. Egidi MF, Trofe J, Reed L, Gaber LW, **Alloway RR**, Shokouh-Amiri MH, Stratta RJ, Gaber AO. Risk factors for polyoma virus (BK): comparative analysis in kidney and pancreas transplants. Seventh World Congress of the International Pancreas and Islet Transplant Association. Sydney, Australia, August 1999.
47. MF Egidi, J Trofe, RJ Stratta, SD Flax, LW Gaber, HS Amiri, M Jones, NA Khan, SR Vera, HP Grewal, **RR Alloway**, AO Gaber. Post transplant lymphoproliferative disorders: therapeutic approach and outcome in solid organ transplantation. First Joint Annual Meeting of the American Society of Transplant Surgeons and the American Society of Transplantation. Chicago IL. May 2000.
48. HS Amiri, A Lo, K Hardinger, **RR Alloway**, J Trofe, HP Grewal, SR Vera, T Anderson, T Kizilisik, AO Gaber. A low dose, short course of Mycophenolate Mofetil (MMF) in combination with Tacrolimus after adult liver transplantation. First Joint Annual Meeting of the American Society of Transplant Surgeons and the American Society of Transplantation. Chicago IL. May 2000.

49. MR Honaker, HS Amiri, **RR Alloway**, HP Grewal, K Hardinger, TA Kizilisik, T Bagous, J Trofe, SR Vera, AO Gaber. Evolving experience of HBV prophylaxis in liver transplant recipients. First Joint Annual Meeting of the American Society of Transplant Surgeons and the American Society of Transplantation. Chicago IL. May 2000.
50. Tuteja S, , Meier-Kriesche H, Streetman DS, Johnson JA, Gaber AO. The effect of gender on ketoconazole induced changes in tacrolimus pharmacokinetics. First Joint Annual Meeting of the American Society of Transplant Surgeons and the American Society of Transplantation. Chicago IL. May 2000.
51. DK Hathaway, RP Winsett, **RR Alloway**, AK Cashion, MA Smith, MN Wicks, RJ Stratta, AO Gaber. Immunosuppressant side effect profile of patients one two twenty years posttransplant. First Joint Annual Meeting of the American Society of Transplant Surgeons and the American Society of Transplantation. Chicago IL. May 2000.
52. MF Egidi, J Trofe, A Lo, RJ Stratta, SR Vera, HP Grewal, MH Amiri, A Salloum, LW Gaber, **RR Alloway**, AO Gaber. Risk factors predisposing liver and kidney transplant patients to the development of post transplant diabetes. First Joint Annual Meeting of the American Society of Transplant Surgeons and the American Society of Transplantation. Chicago IL. May 2000.
53. MR Honaker, A Lo, RJ Stratta, MF Egidi, **RR Alloway**, MH Amiri, LW Gaber, HP Grewal, KL Hardinger, AO Gaber. Impact of HCV status in pancreas transplantation: A case controlled study. First Joint Annual Meeting of the American Society of Transplant Surgeons and the American Society of Transplantation. Chicago IL. May 2000.
54. A Lo, RJ Stratta, **RR Alloway**, MF Egidi, H Amiri, HP Grewal, TA Kizilisik, AO Gaber. Limited benefits of induction with monoclonal antibody to interleukin-2 receptor in combination with tacrolimus, mycophenolate mofetil, and steroids in simultaneous kidney-pancreas transplantation. First Joint Annual Meeting of the American Society of Transplant Surgeons and the American Society of Transplantation. Chicago IL. May 2000.
55. A Lo, RJ Stratta, MF Egidi, MH Amiri, HP Grewal, **RR Alloway**, LW Gaber, AO Gaber. Outcomes of simultaneous kidney-pancreas transplantation in African-American recipients. A case controlled study. First Joint Annual Meeting of the American Society of Transplant Surgeons and the American Society of Transplantation. Chicago IL. May 2000.
56. MF Egidi, N Khan, KL Hardinger, LW Gaber, RJ Stratta, J Trofe, **RR Alloway** AO Gaber. Redefining the impact of systemic lupus erythematosus on renal allografts: The need for aggressive surveillance. First Joint Annual Meeting of the American Society of Transplant Surgeons and the American Society of Transplantation. Chicago IL. May 2000.



## **PRESENTATIONS AT SCIENTIFIC MEETINGS**

1. “Low Dose OKT3 Induction Therapy of Cadaveric Transplant Recipients”. XIVth International Congress of the Transplantation Society. August 1992.
2. “Conversion From Cyclosporine to FK-506 in Kidney, Kidney/pancreas, and Pancreas Alone Transplant Recipients. A Single Center Experience. Minneapolis Transplant Congress: New Immunosuppressive Drugs, Minneapolis, Minnesota, August 1995.
3. “Effect of Gut Metabolism on Tacrolimus Bioavailability in Renal Transplant Recipients”. American Society of Transplantation Surgeons Annual Meeting, Chicago Illinois, May 1997.
4. “An Open-Labeled Single Center Bioequivalence Comparison of Sandimmune and Neoral versus Sang-35 Cyclosporine”. American Society of Transplantation Physicians Annual Meeting, Chicago, Illinois, May 1997.
5. “Bioequivalence of Sang-35 and Neoral for cyclosporine metabolites in stable renal transplant patients. American Society of Transplant Physicians, Chicago Illinois, May 1998.

**PRESENTATIONS AT SCIENTIFIC MEETINGS by TRAINEES**

1. Chaballa M. “Five year followup of a prospective randomized double-blind study comparing standard versus low dose OKT3 induction therapy in renal allograft recipients”. American Society of Transplantation Physicians, oral presentation, Chicago IL, May 1997.
2. Hurst GC. “Preliminary experience with midodrine in kidney/pancreas transplant patients experiencing orthostatic hypotension”. American Society of Transplant Physicians, oral presentation, Chicago Illinois, May 1998.
3. Hurst GC. “ Continued loss of bone density one year post kidney transplant despite preemptive therapy”. American Society of Transplant Physicians, oral presentation, Chicago Illinois, May 1998
4. Trofe J. “Risk factors for Polyoma Virus: A comparative analysis in kidney-pancreas and kidney transplants”. 18<sup>th</sup> annual meeting of the American Society of Transplantation. Oral presentation, Chicago IL. May 1999.
5. Trofe J. “Thymoglobulin for the prophylaxis or treatment of rejection in pancreas allograft recipients: Results of the US compassionate use experience”. 18<sup>th</sup> annual meeting of the American Society of Transplantation. Oral presentation, Chicago IL. May 1999.
6. Trofe J. “Thymoglobulin use in pancreas transplantation”. 7<sup>th</sup> World Congress of the International Pancreas and Islet Transplant Association. Oral presentation, Sydney, Australia, August 1999.
7. Lo A. “Relationship of histological and clinical features of first acute rejection on recurrent rejection and pancreas failure.” First Joint Annual Meeting of the American Society of Transplant Surgeons and the American Society of Transplantation. Oral presentation. Chicago IL. May 2000.
8. Lo A. “Importance of surveillance biopsy monitoring in solitary pancreas transplant patients receiving tacrolimus and mycophenolate mofetil. First Joint Annual Meeting of the American Society of Transplant Surgeons and the American Society of Transplantation. Oral presentation. Chicago IL. May 2000.
9. Lo A. “Patterns of CMV infection in SKPT recipients receiving FK, MMF, and prednisone with ganciclovir prophylaxis.” International Transplantation Society Meeting. Oral presentation, Rome Italy. August 2000.
10. A Lo,. Patterns of cytomegalovirus infection in simultaneous kidney-pancreas transplant recipients receiving tacrolimus, mycophenolate mofetil, and prednisone with ganciclovir prophylaxis. The XVIII International Congress of the Transplantation Society, Oral Presentation, Rome Italy, August 2000.

11. A Lo. Outcomes of simultaneous kidney-pancreas transplantation in African-American recipients: A case control study. The XVIII International Congress of the Transplantation Society, Poster Presentation, Rome Italy, August 2000.
12. A Lo,. Limited benefits of induction with monoclonal antibody to interleukin-2 receptor in simultaneous kidney-pancreas transplantation. The XVIII International Congress of the Transplantation Society, Poster presentation, Rome Italy, August 2000.
13. Aull M, Long-term Graft Function in Renal Transplantation using Non-Heart-beating Donors. *Transplantation 2001*, Oral Presentation Chicago, Illinois, May 2001. *Recipient of a Young Investigator Award*
14. Aull M, Experience with 274 Cardiac Transplant Recipients Post-Transplant Lymphoproliferative Disorder: A Report from the Israel Penn Transplant Tumor Registry. *Transplantation 2001*: Oral Presentation Chicago, Illinois, May 2001.
15. Aull M Transmission of Donor Malignancy during Renal Transplantation: A Report from the Israel Penn International Transplant Tumor Registry. *Transplantation 2001* Oral Presentation Chicago, Illinois, May 2001.

**INVITED PRESENTATIONS**

1. "Current Concepts of FK-506", Transplant Conference, UT Bowld Hospital, September 1990.
2. "Current Cholesterol Screenings", Tri Beta, Christian Brothers College, Memphis, September, 1990.
3. "Individual Chemotherapeutic Agents", University of Tennessee, Memphis, Van Vleet Cancer Center, June, October 1991.
4. "The Role of Monoclonal and Polyclonal Antibodies in Transplantation", Upjohn Pharmaceutical corporation Annual Meeting, French Quarter Inn, Memphis, April 1992.
5. "The Role of Monoclonal and Polyclonal Antibodies in Transplantation", Upjohn Pharmaceutical corporation seminar Annual Meeting, Chicago, June 1992.
6. "The Role of Monoclonal and Polyclonal Antibodies in Transplantation and Results of a Prospective, Randomized Double-Blind Study Comparing Standard Versus Low Dose OKT3 Induction Therapy", Symposium on Transplantation Immunology, Ochsner Clinic, New Orleans, December 1992.
7. "Pharmacologic and Pharmacokinetic Comparison of Antifungal Agents", Pfizer Laboratories, January, February, April 1993.
8. "Pharmacologic and Pharmacokinetic Comparison of Antifungal Agents, Arkansas Association of Hospital Pharmacists", Annual Convention, Hospital Academy Seminar, Fort Smith, Arkansas, June 1993.
9. "Over-the-Counter Medications to Avoid in Hypertensive Patients", University of Tennessee Medical Group, January 1994.
10. "Safe Administration of ATGAM", Tulane University, Transplantation Nursing Staff, Teleconference, February 1994.
11. "Description of a Traineeship in Immunotherapeutics", Twenty-fourth Annual Tennessee Society of Hospital Pharmacists Meeting, March 1994.
12. "Kidney Transplant Case History of CMV Infection", Roundtable Discussion, American College of Clinical Pharmacy, August, 1994.
13. "Demographic and Clinical factors Affecting TCR Expression During and After OKT3 Treatment", The American Society of Nephrology, October 1994.
14. "An Overview of Transplantation Activities at the University of Tennessee, UT Bowld Hospital", University of Tennessee, Board of Trustees, February 1995.

15. "Clinical Monitoring of OKT3 Therapy in the Transplant Patient", University of Tennessee, College of Pharmacy, Department of Clinical Pharmacy, Faculty Research Seminar, May 1995.
16. "The Use of Tacrolimus in Renal Transplant Recipients", St. Mary Hospital, Renal Transplant Division, Grand Rapids, Michigan, August, 1995.
17. "CellCept: A Novel Immunosuppressant for Prevention of Renal Allograft Rejection", Nationwide Pharmacy Tele-Conference, Hoffman LaRoche, Inc. August-October 1995.
18. "The Use of Tacrolimus in Renal Transplant Recipients", Harper Hospital, The Detroit Medical Center, Wayne State University, Detroit, Michigan, November, 1995.
19. "Pharmaceutical Care of the Transplant Patient", The Tennessee Society of Home Care, Nashville, TN, March 1996.
20. "Immunosuppressive Management of the Transplant Patient", Medshares Home Care Company, Regional Meeting, May 1996.
21. "Focusing on Nursing Involvement in Multidisciplinary Research", Twenty-seventh Annual National Research Development Conference, Memphis, TN June 1996.
22. "Pharmaceuticals in Transplantation", United Resources Networks, A Course in Transplantation for Case Managers, Phoenix, AZ, November 1996.
23. "Immunosuppressive Therapy of the Liver Transplant Patient", University of Tennessee, Division of Gastroenterology ,Pathophysiology Conference, Memphis, Tennessee, April 1997.
24. New Advances in Immunosuppressive Therapy in the Transplant Patient, University of Tennessee, Division of Endocrinology , Interhospital Grand Rounds, Memphis, Tennessee, April 1997.
25. An open labeled single center bioequivalence comparison of Sandimmune and Neoral versus Sang-35 cyclosporine. Clinical Transplant Pharmacists Advisory Meeting, Seattle Washington, June 1997.
26. Effect of gut metabolism on tacrolimus bioavailability in renal transplant recipients. Clinical Transplant Pharmacists Advisory Meeting, Seattle Washington, June 1997.
27. Immunosuppressive Philosophy and Management of the Transplant Patient, Ortho Biotech, National Sales Specialist Training School, Newark, New Jersey, July 1997.
28. Immunosuppressive Management of the Transplant Patient, UT Bowld Hospital , Transplant Course, August, September 1997.

29. Immunosuppressive Philosophy and Management of the Transplant Patient, Fujisawa, National Sales Specialist Training School, Deerfield , Illinois, October 1997.
30. Results of US Trials with Generic cyclosporine in Renal Transplant recipients The Memphis Experience. 1997 American Society of Nephrology, Annual Meeting, Satellite symposium, November 1997.
31. Generic Immunosuppressants: A good idea or not? 1997 American Society of Health System Pharmacists, Satellite symposium, December 1997.
32. Transplant Immunosuppression in 1998: State of the Art, Antibody Therapy in Transplantation. 1997 American Society of Health System Pharmacists, Satellite symposium, December 1997.
33. An Overview of Monoclonal and Polyclonal Antibody Therapy and its Monitoring, LeBonheur Children's Hospital, Nephrology and Gastroenterology Conference, March 1994.
34. Overview of Immunosuppression in Transplantation, Zenapax Use in Transplantation. Nova Factor, Zenapax Project Group, Memphis, TN, February 1998.
35. Bioequivalence of cyclosporine and metabolites between Sang-35 and Neoral, SangStat Medical Corporation, National Sales Specialist Training School, Palo Alto, CA, April 1998.
36. The clinical development of Sang35. University of Chicago, Transplant Division, Chicago Illinois, September 1998.
37. An update on antibody therapy in transplantation. University of Chicago, Transplant Division, Chicago Illinois, September 1998.
38. Update on cyclosporine pharmacokinetics and formulations. Midwestern University, Chicago College of Pharmacy, Chicago, Illinois, November 1998.
39. An update on new immunosuppressive agents. 1998 Annual Meeting, American College of Clinical Pharmacy, Cincinnati, Ohio, November 1998.
40. Immunosuppressive Philosophy and Management of the Transplant Patient, Fujisawa, National Sales Specialist Training School, Deerfield , Illinois, November 1998.
41. The Development of SangCyA, a generic cyclosporine. LeBonheur Childrens Hospital, Memphis, Tennessee, February 1999.
42. The Development of SangCyA, a generic cyclosporine. St. Jude Children's Research Hospital, Memphis, Tennessee, March 1999.
43. Immunology Overview and Immunosuppression, Barnes Jewish Hospital Grand Rounds, St. Louis Missouri, March 1999.

44. Critical Drugs In transplantation: Methods of Evaluation. Determination of Therapeutic Equivalence: The pharmacists perspective. 1999 Annual APhA meeting, Satellite Symposium, San Antonio, Texas, March 1999.
45. TOR Inhibitors: A new approach to Immunosuppression. Review of the Clinical Trials: Efficacy and Safety. Moderator and Speaker. Satellite Symposium, American College of Clinical Pharmacy, International Congress on Clinical Pharmacy, Orlando. Florida, April 1999.
46. Bioequivalence testing of SangCya and Neoral in Stable Renal Transplant Recipients, National Conference , SangStat Medical Corporation, April 1999.
47. Immunosuppressive Philosophy and Management of the Transplant Patient, Fujisawa, National Sales Specialist Training School, Deerfield , Illinois, May 1999.
48. The Development of Thymoglobulin for use in Transplantation. LeBonheur Childrens Hospital, Memphis, Tennessee, May 1999.
49. Development of Generic Immunosuppressants, International Transplant Nurses Society, Toronto, Canada. August 1999.
50. Update on Current Immunosuppressive Therapies. Medimmune Training Course, Gaithersberg Maryland. August 1999.
51. Pancreas Transplantation and Subsequent Challenges. Memphis Area Society for Parenteral and Enteral Nutrition. Memphis. Tennessee. September 1999.
52. Pharmacists Opportunities for Collaborative Research in Transplantation. University of Memphis and University of Tennessee, Graduate Program in Health Science Administration Program. Memphis, Tennessee, September 1999.
53. Generic Drug Development: Is it Adequate for Immunosuppressants. International Transplant Nurses Society, Birmingham, Alabama. October 1999.
54. Current Status of Immunosuppressive Drug Development in Transplantation, Wichita, Kansas Medical Center Transplant Grand Rounds, Wichita, Kansas, October, 1999.
55. Current Status of Immunosuppressive Drug Development in Transplantation, University of Vanderbilt Transplant Grand Rounds, Nashville, Tennessee, October 1999.
56. The Use of Cyclosporine Generic Derivatives in Adult Transplant Solid Organ Recipients: Implications For Pediatric Transplantation", University of Pittsburgh Children's Hospital Transplant Grand Rounds, Pittsburgh, Pennsylvania, November, 1999.
57. Update on New Immunosuppressive Therapies. Breaking Issues. Section of Clinical Specialists of the American Society of Health-System Pharmacists. Orlando Florida, December 1999.

58. The Future of Generic Immunosuppressive Drug Development in Transplantation, University of Utah Transplant Grand Rounds, Salt Lake City, Utah, January, 2000.
59. Immunosuppressive Drug Therapy in Transplantation, University of Utah Pharmacy Services, Salt Lake City, Utah, January, 2000.
60. "Generic Immunosuppressive Drug Therapy", Austin Diagnostic Clinic Transplant Grand Rounds, Austin, Texas, January, 2000.
61. "Overview of Generic Drug Development", Hospital and Managed Care Pharmacy Group of San Antonio, San Antonio, Texas, January 2000.
62. Generic immunosuppressive drug development in transplantation. Cincinnati Children's Medical Center, January, 2000.
63. "Cyclosporine Generic Derivatives: Use and Misuse in Transplantation", Christ Hospital Transplant Grand Rounds, February, 2000.
64. "Principles and Practice of Generic Drug Development in Solid Organ Transplantation," University of Cincinnati Transplant Seminar, February, 2000.
65. Development of Sang-35, a Generic Cyclosporine. Formulary Review Committee, University of Florida, Gainesville, Florida, February 2000.
66. "Generic Drugs in Transplantation", Pharmacists Training Seminar, Abbott Laboratories, Dallas, Texas, February, 2000.
67. "Cyclosporine Generic Drug Development", Transplant Grand Rounds, Ochsner Medical Foundation, New Orleans, Louisiana, February, 2000.
68. Are FDA guidelines adequate for Development of Generic Immunosuppressants? Transplant Grand Rounds, University of Michigan, Ann Harbor, Michigan, March 2000.
69. "Transplant 2005", Annual American Nephrology Nurses Association Meeting. Nashville, Tennessee. April 2000.
70. "Update on Immunosuppressive Therapy: A Pharmacists Perspective", Memphis Area Pharmacist Society. Memphis Tennessee, April 2000.
71. "Generic Immunosuppressant Use in Transplantation", United Network for Organ Sharing Annual Meeting, Baltimore Maryland, April 2000.
72. "Generic Drugs in Transplantation", Physician's Training Seminar, Abbott Laboratories, Dallas, Texas, April 2000.
73. "The Clinical Relevance of Bioequivalence" Transplant Advisory Meeting, Abbott/SangStat, Vancouver British Columbia, April 2000.

74. "Update on Immunosuppressive Therapy for the Transplant Coordinator", Kansas City Transplant Coordinators Annual Meeting, Kansas City, Missouri, May 2000.
75. "The Clinical Relevance of Bioequivalence and the Impact of Cyclosporine Generics" Transplant Grand Rounds, Emory University Atlanta, Georgia, June 2000.
76. "Transplantation Pharmacology", Transplant Fellows Conference 2000, Vail Colorado, July 2000.
77. "Update on Immunosuppressive Therapy and the Impact on the Development of CMV", Medimmune Training Course, Baltimore, Maryland, July 2000.
78. "Transplant 2005", ITNS Golden Triangle Chapter Meeting. Pittsburgh Pennsylvania. October 2000.
79. "Gengraf Transplant Patient Data Overview", Virginia Formulary. Richmond Virginia. November 2000.
80. "Transplant, Past, Present and Future", Maximizing the Pharmacists Role in Transplant Patient Management: Current Best Practices". Marco Island Florida, January 2001.
81. "The Scientific Data on Cyclosporine Generics: Pharmacokinetics", American Society of Transplantation, St. Louis Missouri, February 2001.

#### **TEACHING RESPONSIBILITIES: LECTURES AND COURSES**

1. Current Status of Kidney Transplantation, University of Tennessee, Memphis, College of Pharmacy, 2000.
2. Immunosuppressive Philosophy and Management of the Transplant Patient, University of Tennessee, Memphis, FNP Training Class, May 1999.
3. Principles of Immunosuppressive Regimens. University of Tennessee, Memphis, College of Pharmacy, 1999.
4. Immunology Overview and Immunosuppression, UT Bowld Transplant Nursing Course, Memphis, Tennessee, March 1999.
5. Pharmacologic Management of Solid Organ Transplants at the University of Tennessee, UT Bowld Nursing Staff, July 1997, February 1998.

6. Clinical Laboratory Monitoring-Immunology, University of Tennessee, Memphis, College of Pharmacy, January 1997, 1998, 1999, 2000.
7. Clinical Pharmacokinetics of Immunosuppressive Agents, University of Tennessee, Memphis, College of Pharmacy, February 1996, November 1997.
8. Pharmacologic Considerations of Transplant Therapy for the Dental Patient, University of Tennessee, College of Dentistry, Postgraduate Periodontics, April 1995, June 1998.
9. Overview of Transplantation Immunology, University of Tennessee, Memphis, College of Pharmacy, February 1995, 1996, 1997, 1998, 1999.
10. Overview of Clinical Immunology, University of Tennessee, Memphis, College of Pharmacy, February 1995, 1996.
11. Immunosuppressive Agents Used in Solid Organ Transplantation and Their Impact upon the Patients Physical Abilities, UT Bowld Hospital, Physical Therapy Department, Memphis, September 1994, 1996.
12. Immunosuppressive Agents Utilized in Solid Organ Transplantation and Their Monitoring, Preceptorship in Solid Organ Transplantation, University of Tennessee, Department of Surgery, Division of Transplantation, Memphis, February 1994, September 1994.
13. Immunosuppressive Agents Used in Solid Organ Transplantation, University of Tennessee, Memphis, College of Pharmacy, February 1994, 1995, 1996, 1997, 1998.
14. Roles and Issues for Advanced Nursing Practice-Conducting Collaborative Research, University of Tennessee, Memphis, College of Nursing, February 1994, 1995.
15. Extra-Renal Solid Organ Transplantation, University of Tennessee, Memphis, College of Pharmacy, February 1994, 1997.
16. A Pharmacist's Role in Transplantation, University of Tennessee, Memphis, College of Pharmacy, January 1994, 1995.
17. Pharmacologic Management of Solid Organ Transplants at the University of Tennessee, University of Tennessee, College of Nursing Students, Semesterly, 1992, 1993, 1994, 1995.
18. Medical Management of the Renal Transplant Patient, University of Tennessee, Memphis, College of Pharmacy, September 1992.
19. Parathyroid Hormone, University of Tennessee, Memphis, College of Pharmacy, March 1992, 1993.
20. Individual Chemotherapeutic Agents, University of Tennessee, Memphis, Van Fleet Cancer Center, June, October 1991.

21. Pharmacist Role in Transplantation, University of Tennessee, Memphis, College of Pharmacy, January, June 1991; March 1992.
22. Pharmacologic Management of Liver Transplants, Nursing Critical Care Course, UT Bowld Hospital, October 1991.
23. Pharmacologic Management of Kidney Transplants, Nursing Critical Care Course, UT Bowld Hospital, October 1991.
24. Pharmacologic Management of Pancreas Transplants, Nursing Critical Care Course, UT Bowld Hospital, October 1991.
25. "OKT3 Protocol", Nursing Staff Inservice UT Bowld Hospital, May 1990.
26. "Management of Electrolytes", Nursing Staff Inservice, UT Bowld Hospital, March 1990.
27. "Treatment of DVT and PE", Nursing Staff Inservice, UT Bowld Hospital, February 1990.
28. "Overview of the Management of Parkinson's Disease", Pharm.D. Students, Veterans Administration Medical Center, July 1989.
29. "Anticoagulation of DVT and PE", Pharm.D. Students, Veterans Administration Medical Center, July 1989.
30. "Treatment of Ascites", Pharm.D. Students, Veterans Administration Medical Center, July 1989.
31. "Expression of Opinions on the Job", ITTG, Veterans Administration Medical Center, Memphis, TN, May 1989.
32. "Unproven Arthritis Remedies", University of Tennessee, Memphis College of Pharmacy, April 1989, 1990, 1991, 1992, 1993.
33. "Use of Heparin and Warfarin", University of Tennessee, Memphis, Neurology Residents, April 1989.
34. "Anticoagulation of DVT and PE", Veterans Administration Medical Center, Medical Residents, Memphis, TN, October 1988.
35. "Drug Review of Cefitin", Veterans Administration Medical Center, Pharmacy Students Memphis, TN, March 1988.
36. "Concentration of Aminoglycosides in Bronchial Secretions", Pharmacy Service, LeBonheur Children's Hospital, Memphis, TN, February 1988.

37. "Seasonal Affective Disorders", Journal Club, Midtown Mental Health Institute, Memphis, TN, January 1988.
38. "Treatment of Inflammatory Bowel Disease", Pharmacy Service, Regional Medical Center, Memphis, TN, January 1988.
39. "Aminoglycoside Pharmacokinetics", Medicine Team, Regional Medical Center, Memphis, TN, November 1987.
40. "Therapeutic Management of Cystic Fibrosis Patients", Inservice Training, Special Care Unit Nurses and Respiratory Therapists, LeBonheur Children's Hospital, Memphis, TN, April 1984.

## PROJECTS

1. Coordination of University of Tennessee Division of Transplantation Preceptorship, SangStat Medical Corporation, University of Tennessee, Department of Surgery, Division of Transplantation, Memphis, September 1994, 6 participants.
2. ASHP Residency Accreditation, Specialized Residency in Transplantation, submitted March 2000
3. Coordination of "Rapamycin Day", University of Tennessee, Memphis, December 1999.
4. Coordination of University of Tennessee Division of Transplantation Preceptorship, Wyeth Ayerst Research Laboratories., University of Tennessee, Department of Surgery, Division of Transplantation, Memphis, November 1999, 2 participants.
5. Participant of Fujisawa Clinical Pharmacy Advisory Group, March 1999.
6. Moderator of Roche Clinical Pharmacy Advisory Group, February 1999.
7. Moderator of Zenapax Kidney/Pancreas Roche Study Group, April 1998.
8. Initiate the UT Bowld Clinical Pharmacy Working Group, July 1997.
9. Initiation of corporate relationships between SangStat Medical Corporation, the Transplant Pharmacy and the University of Tennessee, Transplant Division, July 1996.
10. Initiation of corporate relationships between MedShares and the University of Tennessee, Transplant Division, July 1996.
11. Designing Outcomes Research for the Transplant Pharmacy, Kansas City, Missouri, June 1996.
12. Organized a visit from Baxter Homehealth Care Division to discuss product development with a focus upon the transplantation market.
13. Creating a jointly funding GI/Nutritional Support Clinical Pharmacist between UT Bowld Hospital and UTMG.
14. Pilot center for establishing a Disease State Management System with SangStat Medical Corporation, The Transplant Pharmacy, May 1996.
15. Establishing the involvement of the College of Social Work within UT Bowld Hospital, Transplant Division, March 1996.
16. JCAHO Site Survey Response, November 1995.

17. Coordination of University of Tennessee Division of Transplantation Preceptorship, Sandoz Pharmaceuticals Corporation, University of Tennessee, Department of Surgery, Division of Transplantation, Memphis, September 1995, 5 participants.
18. Patient Medication Use Education, poster presentation, JCAHO site survey, April 1995.
19. Coordination of University of Tennessee Division of Transplantation Preceptorship, Ortho Biotech, Fujisawa USA, Inc., University of Tennessee, Department of Surgery, Division of Transplantation, Memphis, September 1994, 7 participants.
20. Moderator and Organizer, Managing CMV Disease in Transplant Recipients: A Roundtable Discussion. American College of Clinical Pharmacy, St. Louis, Missouri, August 1994.
21. Coordination of University of Tennessee Division of Transplantation Preceptorship, Fujisawa USA, Inc., University of Tennessee, Department of Surgery, Division of Transplantation, Memphis, April 1994, 3 participants.
22. Acquiring funding for the establishment of a Transplantation/Critical Care Pharmacy Residency, UT Bowld Hospital, January 1994.
23. Comparison of Oral Antifungal Agents, University of Tennessee, Drug Information Center, Allied Pharmacy Management Inc., July 1993.
24. UT Bowld Hospital, Transplant Patient Medicine Education Manual, July 1992.
25. University of Tennessee, Department of Surgery, Division of Transplantation, Surgery Resident's Manual for Transplantation, July 1992.
26. Medical Management of Ulcerative Colitis: Hypercolitis, Hypercard instructional stack for Gastrointestinal Medicine, April 1992
27. Implementation of UT Bowld Hospital Formulary, UT Bowld, November 1991.
28. Implementation of Self Administration of Medications to Transplant Patients, UT Bowld, January 1991.
29. Implementation of Adverse Drug Reaction Reporting System, UT Bowld, August, 1989.
30. Implementation of course/faculty evaluation at the University of Tennessee, Memphis College of Pharmacy, 1986.
31. SAPHa Drug Fair Coordinator, 1985

## **Community Service**

1. Careers in the Pharmacy, On-Site Day Visit, Memphis City School, Optional Schools Program, East High School student, May 1995.
2. Minority Challenge Program, High School Graduates, University of Tennessee, June-August 1994.
3. Careers in the Health Sciences, College and Career Day, East High School students, April 1994.
4. University of Tennessee Medical Group Radio Program, "Medicine and Drugs"; WMC-79 Memphis TN, June 1993, January 1994.

**RESEARCH FUNDING: CURRENT**

1. "An open-label, comparative trial of two daclizumab dosing strategies versus no induction treatment in combination with tacrolimus, mycophenolate mofetil, and steroids for the prevention of acute allograft rejection in simultaneous kidney/pancreas transplant recipients." Funded by Roche Laboratories-\$4,316,510, Co-principal investigator, 50% effort.
2. "A prospective, randomized, multicenter trial of early corticosteroid cessation vs. long term maintenance corticosteroid therapy in primary renal allograft recipients treatment with tacrolimus and mycophenolate mofetil." Funded by Fujisawa Pharmaceuticals-\$440,000, Co- Investigator, 10% effort.
3. "Cytogam Pharmacokinetic and Pharmacodynamic markers in the treatment of CMV disease." Funded by Medimmune-\$50,000, Co-Investigator, 20% effort.
4. "A Prospective, pilot study of early corticosteroid cessation with Zenapax, Prograf, Cellcept, and Rapamune in High Immunologic Risk Renal Transplant Recipients" Funded by Roche Laboratories-\$204,565, Co-investigator, 10% effort.
5. "A Prospective Pilot Study of Corticosteroid Avoidance with Prograf, Cellcept and Rapamune that Avoids Induction Therapy in Renal Transplant Patients" Funded by Wyeth Ayerst Pharmaceutical Company -\$167,386, Co-investigator, 10% effort.
6. "An open-label study to evaluate the safety and efficacy of early (5 day) steroid cessation in de novo renal allograft recipients treated with Simulect induction and Prograf in combination with Rapamune." Funded by Wyeth Ayerst Pharmaceutical Company –In negotiation, Co-investigator, 10% effort.
7. "A multicenter, randomized, partially-blinded study of the safety and efficacy of FTY720 combined with corticosteroids and full or reduced dose Neoral in de novo adult renal transplant recipients." Funded Novartis Pharmaceutical Company –In negotiation, Co-investigator, 10% effort.

**RESEARCH FUNDING: PENDING**

1. "Pharmacokinetic and Pharmacodynamic evaluation of open-label, comparative trial of two daclizumab dosing strategies versus no induction treatment in combination with tacrolimus, mycophenolate mofetil, and steroids for the prevention of acute allograft rejection in simultaneous kidney/pancreas transplant recipients." Funding in negotiation with Roche Laboratories- \$54,000, Co-principal investigator, 50% effort.
2. "Glucocorticoid pharmacokinetics during rapid steroid withdrawal and prolonged steroid immunosuppression in renal transplant recipients." Funding in negotiation with Fujisawa, Co- investigator, 10% effort.
3. "Corticosteroid-free, Calcineurin-sparing Immunosuppression Protocol for HLA-Identical Living Donor Renal Transplant Recipients". Funding in negotiation with Roche Laboratories, Co- investigator, 10% effort.
4. "A Phase 2, Randomized Multicenter, double-blind safety study of ISA 247 and Cyclosporine in post renal Transpalnt Patients". Funding in negotiation with Isotechnika, Co- investigator, 10% effort.
5. "WAR 316". Funding in negotiation with Wyeth Ayerst, Co- investigator, 10% effort.

**RESEARCH FUNDING: PREVIOUS**

1. Educational Grant from Upjohn, \$7,500.
2. Educational Grant from Hoechst-Roussel, \$500.
3. Educational Grant from Pfizer Pharmaceuticals, \$500.
4. "Immunoglobulin Prophylaxis in Recipients of Solid Organ Transplants." Funded by Cutter Biological, \$26,000; Collaborating Investigator, 10% effort.
5. "Randomized Double-Blind Study Comparing Standard Versus Low Dose OKT3 Induction Therapy." Funded by Ortho Pharmaceuticals, \$20,000; Principal Investigator, 50% effort.
6. "Oral 256U87 Suppression of Cytomegalovirus Infection and Disease in Renal Allograft Recipients." Funded by Burroughs Wellcome Company, \$117,768; Collaborating Investigator, 10% effort.
7. "A Multicenter Randomized Comparative Study Comparing Sandimmune Oral Solution and OG37-325 Oral Solution in the Prevention of Renal Allograft Rejection." Funded by Sandoz Pharmaceuticals Corporation, \$125,760; Co-Principal Investigator, 25% effort.
8. "A Placebo-Controlled, Double-Blind Random-Off Evaluation of the Efficacy of Oral Torsemide (Demadex) in Patients with Chronic Renal Insufficiency". Funded by Boehringer Mannheim Pharmaceuticals, \$52,430; Co-Investigator, 25% effort.
9. "An Open-Label Safety and Tolerance Study of Peripheral Vein Administration of Equine Antithymocyte Globulin (ATGAM)". Funded by the Upjohn Company, \$250,000-drug supply/\$12,500-labor; Co-Principal Investigator, 50% effort.
10. IMx Tacrolimus Assay Investigation Device Evaluation, Funded by Abbott Laboratories, Budget in negotiation. Collaborating Investigator, 10% effort.
11. "A Prospective, Randomized, Comparative Multicenter Safety and Tolerability Study of Neoral versus Sandimmune in Primary Liver Transplant Patients." Funded by Sandoz Pharmaceuticals Corporation, 45,000, Co-principal Investigator, 10% effort.
12. "A Double-blinded Randomized Multicenter Phase III Clinical Trial of Thymoglobulin Versus Atgam in the Treatment of Acute Graft Rejection Episodes following Renal Transplantation in Adults." Funded by SangStat Medical Corporation, \$200,000, Co-principal Investigator, 10% effort.
13. "Effects of FK-506 (Prograf) on Hyperlipidemia After Successful Renal Transplantation." Funded by Fujisawa Pharmaceuticals, \$13,400, Co-principal Investigator, 10% effort.

14. "Multicenter, Open-Label Study of the Safety and Tolerability of Neoral in Stable Renal Transplant Patients." Sandoz Pharmaceuticals Corporation, \$38,000, Co-principal Investigator, 10% effort.
15. "A Multicenter, Randomized, Double-blind, Placebo, Controlled Trial of SDZ CHI 621 for the Prevention of Acute Cellular Rejection in Renal Allograft Recipients." Funded by Sandoz Pharmaceuticals Corporation, \$16,400, Co-principal Investigator, 10% effort.
16. Educational Grant from SangStat Medical Corporation in support of Transplant Residency, \$10,000.
17. "Pharmacokinetic and primary prophylaxis with tacrolimus as part of a quadruple, sequential immunosuppressive drug regimen in black cadaveric renal transplant recipients." Funded by Fujisawa Pharmaceuticals, \$120,000, Co-principal Investigator, 10% effort.
18. "A Double-Blind, Randomized, Placebo-Controlled, Multi-Center Trial to Evaluate the Efficacy and Safety of Two Doses of Lexipafant for the Treatment of Acute Pancreatitis." Funded by British Biotech, \$55,000, Collaborating Investigator, 10% effort.
19. "An Open Labeled, Prospective Study of the Effects of Tacrolimus Based Immunosuppressive Regimen as Primary Therapy in Liver Transplant Recipients." Funded by Fujisawa Pharmaceuticals-\$56,000 Co-principal Investigator, 10% effort.
20. "An Open Label Single Center Comparison of Neoral and Generic Cyclosporine Bioequivalence in Stable Adult Renal Transplant Recipients." Funded by SangStat Medical Corporation-\$115,200 Co-principal Investigator, 50% effort.
21. "An Open Label Single Center Comparison of Sandimmune and Generic Cyclosporine Bioequivalence in Stable Adult Renal Transplant Recipients." Funded by SangStat Medical Corporation-\$57,600, Co-principal Investigator, 50% effort.
22. "A Double-Blind, Comparative Study of the Effect of Two Dose Levels of Sirolimus Versus Azathioprine, Administered Concomitantly with Standard Immunosuppressive Therapy, in Renal Allograft Recipients." Funded by Wyeth-Ayerst-\$372,480, Co-principal Investigator, 10% effort.
23. "Five year followup of a prospective randomized double-blind study comparing standard versus low dose OKT3 induction therapy in renal allograft recipients." Funded by Ortho Biotech-\$25,000, Co-principal Investigator, 10% effort.
24. "Phase 1/2 Trial of Murine Monoclonal Antibody Medi-500 (T10B9) in the Treatment of Acute Renal Allograft Rejection." Funded by Medimmune-\$1,000, Co-principal Investigator, 10% effort.

25. A Pilot Comparative, Controlled Evaluation of the Monitoring of cyclosporine in Whole Blood Peripheral Venous Samples versus Filter Paper Extraction of Capillary Venous Samples. Funded by SangStat-\$10,000, Principal Investigator, 50% effort.
26. Educational Grant from SangStat Medical Corporation in support of Transplant Residency, \$25,000.
27. "Endothelin-1 Plasma Concentrations in Renal Transplant Patients Receiving Cyclosporine: Racial Differences in Endothelin-1 plasma concentrations in Hypertensive renal transplant recipients taking cyclosporine." Submitted to Roche, Collaborating Investigator, 25% effort.
28. "Endothelin-1 Plasma Concentrations in Renal Transplant Patients Receiving Cyclosporine: Cyclosporine concentration-Endothelin-1 Concentration relationship." Submitted to Roche Collaborating Investigator, 25% effort.
29. Educational Grant from Fujisawa Pharmaceuticals in support of Transplant Residency, \$2,000.
30. "An Open Label Single Center Comparison Longterm Generic Cyclosporine Administration in Stable Adult Renal Transplant Recipients." Funded by SangStat Medical Corporation-\$15,000 Co-principal Investigator, 50% effort
31. Prospective evaluation of consecutive renal allograft recipients receiving a quadruple, sequential, immunosuppressive Drug Regimen of Thymoglobulin, Sang-35 oral solution (cyclosporine), mycophenolate mofetil, and prednisone." Funded by SangStat-\$160,000, Co-Principal Investigator, 50% effort.
32. "A Phase III, randomized, double-blind, placebo controlled multicenter study of the efficacy of odulimomab (ANTILFA) in preventing delayed graft function of cadaveric renal allografts in patients not receiving biological induction immunosuppressive therapy." Funded by IMTIX-\$139,020. Co-Principal Investigator, 50% effort.
33. "A Randomized Comparative Trial of the effect of antilymphocyte induction on tacrolimus plus mycophenolate mofetil maintenance immunosuppression after simultaneous kidney pancreas transplantation." Funded by Fujisawa Pharmaceuticals-\$120,000 , Co-principal Investigator, 10% effort.
34. "Influence of side effect profile on compliance and transplant outcomes." Funded by NATCO-\$10,000. Co-Investigator, 1% effort.
35. "A prospective, randomized, multicenter, controlled study of the CycloTech delivery device in stable solid organ transplant recipients receiving SangCya (Cyclosporine oral solution, USP (modified) 100 mg/mL)" Funded by SangStat-\$78,000, Principal Investigator, 15% effort.
36. "Post Transplant Quality of Life Intervention Study" NIH, NR 004687, 1998-2002. Funding \$2,486,054, Co Investigator 5% effort

37. "An Open Label Pharmacokinetic Comparison of Sang-2000, SangCyA and Neoral in Stable Adult Renal Transplant Recipients." Funded by SangStat-\$85,349, Principal Investigator, 50% effort.
38. Management of Posttransplant Osteoporosis in Women". Funded by Women's Health Research Grant-\$35,780, Co-investigator, 5% effort.
39. Educational Grant from Roche Laboratories in support of abstract data coordination, \$20,000.
40. Educational Grant from Roche Laboratories in support of Transplant Residency, \$20,000.
41. A randomized, open-label, multicenter, efficacy and safety study of Pegasys for the treatment of hepatitis C virus infection administered six to sixty months post liver transplantation Funded by Roche Laboratories-\$105,292, Co investigator, 5% effort. Educational Grant from Innovex in support of Transplant Residency, \$2,000.
42. Educational Grant from Roche Laboratories in support of Transplant Residency, \$1,500.
43. Educational Grant from Abbott Laboratories in support of Transplant Residency, \$1,000.
44. Educational Grant from Wyeth Ayerst Laboratories in support of Transplant Residency, \$900
45. Educational Grant from Abbott Laboratories in support of Transplant Residency, \$1,250.
46. Educational Grant from Liposome Company in support of Transplant Residency, \$250.

47.